Cargando…

Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method

INTRODUCTION: Accurate knowledge of O(6)-methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is important for treatment. However, this test is not always available. Pre-operative diffusion MRI (dMRI) can be used to probe tumour biology using the apparent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rundle-Thiele, Dayle, Day, Bryan, Stringer, Brett, Fay, Michael, Martin, Jennifer, Jeffree, Rosalind L, Thomas, Paul, Bell, Christopher, Salvado, Olivier, Gal, Yaniv, Coulthard, Alan, Crozier, Stuart, Rose, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462980/ https://www.ncbi.nlm.nih.gov/pubmed/26229673 http://dx.doi.org/10.1002/jmrs.103

Ejemplares similares

Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients
por: Rulseh, Aaron Michael, et al.
Publicado: (2019)

Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma
por: MATSUDA, Kenichiro, et al.
Publicado: (2022)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
por: Raghavan, Sudhir, et al.
Publicado: (2020)

Prevention of endometrial cancer through lifestyle Interventions: A systematic review and synthesis
por: Rundle-Thiele, Dayle, et al.
Publicado: (2021)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Classification of Primary Cerebral Lymphoma and Glioblastoma Featuring Dynamic Susceptibility Contrast and Apparent Diffusion Coefficient
por: Eisenhut, Felix, et al.
Publicado: (2020)

The trouble with apparent diffusion coefficient papers
por: Bourne, Roger M
Publicado: (2015)

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
por: Iliadis, Georgios, et al.
Publicado: (2012)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma
por: Akgül, Seçkin, et al.
Publicado: (2019)

Apparent diffusion coefficient of normal adrenal glands
por: Teixeira, Sara Reis, et al.
Publicado: (2016)

Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology
por: Paech, Daniel, et al.
Publicado: (2015)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
por: Kirstein, Anna, et al.
Publicado: (2020)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma
por: Offenhäuser, Carolin, et al.
Publicado: (2018)

Prognostic Value of Apparent Diffusion Coefficient in Oropharyngeal Carcinoma
por: Sistonen, Heli J., et al.
Publicado: (2021)

Differentiation between Primary Cerebral Lymphoma and Glioblastoma Using the Apparent Diffusion Coefficient: Comparison of Three Different ROI Methods
por: Ahn, Sung Jun, et al.
Publicado: (2014)

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
por: Korfiatis, Panagiotis, et al.
Publicado: (2016)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics
por: Tierling, Sascha, et al.
Publicado: (2022)

Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation
por: Liu, Delin, et al.
Publicado: (2022)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Comparison of Apparent Diffusion Coefficient and Intravoxel Incoherent Motion for Differentiating among Glioblastoma, Metastasis, and Lymphoma Focusing on Diffusion-Related Parameter
por: Shim, Woo Hyun, et al.
Publicado: (2015)

NI-14 EVALUATION OF PREOPERATIVE APPARENT DIFFUSION COEFFICIENT (ADC) OF PERITUMORAL LESION FOR PREDICTING SITE PRONE TO RECURRENCE IN PATIENTS WITH GLIOBLASTOMA
por: Matsuda, Kenichiro, et al.
Publicado: (2019)

NI-17 Evaluation of preoperative apparent diffusion coefficient (ADC) of peritumoral FLAIR high lesion and histopathological features in patients with glioblastoma
por: Matsuda, Kenichiro, et al.
Publicado: (2020)

Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma
por: Lopez-Rueda, Antonio, et al.
Publicado: (2023)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

Apparent diffusion coefficient values of normal testis and variations with age
por: Tsili, Athina C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_71g668pn0ucbkgac0p8krdgt6o